Pfizer (PFE) Stock Price, News & Analysis

Company Overview

Pfizer Inc. (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business. Notable products historically and in recent years have included established brands such as Lipitor and Viagra, specialty therapies like Xeljanz and Eliquis (developed and marketed in collaboration with Bristol-Myers Squibb), and vaccines including Prevnar. More recently, Pfizer partnered with BioNTech to develop the Comirnaty COVID-19 vaccine and developed the oral antiviral Paxlovid, reflecting the company’s capabilities across both biologics and small-molecule therapeutics.

Pfizer operates globally with research, manufacturing and commercial operations across North America, Europe, Asia and other regions, serving patients and healthcare systems worldwide. Its growth has been shaped by a series of strategic transactions and partnerships over decades, including major acquisitions that expanded its therapeutic breadth and capabilities. The company emphasizes external collaborations, in-licensing and acquisitions alongside internal R&D to build and sustain its product pipeline.

Leadership and organizational strategy center on sustained investment in research and development, regulatory engagement and global commercial execution. As a large, diversified biopharma, Pfizer balances near-term product commercialization with longer-term innovation efforts aimed at advancing new therapies and vaccines through clinical development and into clinical practice.

Key Stats

• Today's Range: $25.48 to $25.91
• 50-Day Range: $25.31 to $28.56
• 52-Week Range: $23.06 to $28.75
• Volume: 35.52 million shs
• Average Volume: 34.31 million shs
• Market Capitalization: $145.61 billion
• P/E Ratio: 19.44
• Dividend Yield: 6.73%
• Price Target: $28.82
• Consensus Rating: Hold

Pfizer Stock Analysis - MarketRank™

Pfizer scored higher than 77% of companies evaluated by MarketBeat, and ranked 187th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Pfizer has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 strong buy rating, 5 buy ratings, 11 hold ratings, and 3 sell ratings.

Upside Potential

Pfizer has a consensus price target of $28.82, representing about 13.4% upside from its current price of $25.43.

Amount of Analyst Coverage

Pfizer has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -4.35%

Earnings Growth

Earnings for Pfizer are expected to decrease by -4.35% in the coming year, from $2.99 to $2.86 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pfizer is 19.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pfizer is 19.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.14.

Price to Book Value per Share Ratio

Pfizer has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.78% of the float of Pfizer has been sold short.

Short Interest Ratio / Days to Cover

Pfizer has a short interest ratio ("days to cover") of 4.12.

Change versus previous month

Short interest in Pfizer has recently increased by 12.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

Pfizer is a leading dividend payer. It pays a dividend yield of 6.57%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Pfizer has been increasing its dividend for 16 years.

Dividend Coverage

The dividend payout ratio of Pfizer is 131.30%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Pfizer will have a dividend payout ratio of 60.14% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.77

News Sentiment

Pfizer has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 77 news articles for Pfizer this week, compared to 12 articles on an average week.

Search Interest

202 people have searched for PFE on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.

MarketBeat Follows

113 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 232% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pfizer insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.62% of the stock of Pfizer is held by insiders.

Percentage Held by Institutions

68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 3/6 Dividend: 1/23/2026
• Ex-Dividend for 3/6 Dividend: 1/23/2026
• Dividend Payable: 3/06/2026
• Last Earnings: 5/05/2026
• Record date for 6/12 Dividend: 5/08/2026
• Ex-Dividend for 6/12 Dividend: 5/08/2026
• Today: 6/02/2026
• Jefferies Global Healthcare Conference 2026: 6/03/2026
• Goldman Sachs 47th Annual Global Healthcare Conference 2026: 6/08/2026
• Dividend Payable: 6/12/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:PFE
• CIK: 78003
• Web: www.pfizer.com
• Phone: (212) 733-2323
• Fax: 302-655-5049
• Employees: 75,000
• Year Founded: 1849

Price Target and Rating

• Average Price Target for Pfizer: $28.82
• High Price Target: $36.00
• Low Price Target: $25.00
• Potential Upside/Downside: +12.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.31
• Trailing P/E Ratio: 19.44
• Forward P/E Ratio: 8.56
• P/E Growth: N/A
• Net Income: $7.77 billion
• Net Margins: 11.83%
• Pretax Margin: 12.48%
• Return on Equity: 19.44%
• Return on Assets: 8.41%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 1.25
• Quick Ratio: 0.94

Sales & Book Value

• Annual Sales: $62.58 billion
• Price / Sales: 2.33
• Cash Flow: $4.30 per share
• Price / Cash Flow: 5.95
• Book Value: $15.26 per share
• Price / Book: 1.68

Miscellaneous

• Outstanding Shares: 5,699,440,000
• Free Float: 5,664,107,000
• Market Cap: $145.87 billion
• Optionable: Optionable
• Beta: 0.34